We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
KINAXO Biotechnologies and Bayer Vital Collaborate in Phosphoproteomics Biomarker Identification
News

KINAXO Biotechnologies and Bayer Vital Collaborate in Phosphoproteomics Biomarker Identification

KINAXO Biotechnologies and Bayer Vital Collaborate in Phosphoproteomics Biomarker Identification
News

KINAXO Biotechnologies and Bayer Vital Collaborate in Phosphoproteomics Biomarker Identification

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "KINAXO Biotechnologies and Bayer Vital Collaborate in Phosphoproteomics Biomarker Identification"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

KINAXO Biotechnologies GmbH and Bayer Vital GmbH announced that they will enter into collaboration. KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout® for the identification of novel biomarkers in a clinical trial conducted by Bayer Vital.

KINAXO’s phosphoproteomics platform allows annotation and quantification of regulated phosphorylation sites. Since the majority of targeted compounds used as anti-cancer drugs influence cellular signal transduction pathways, analysis of phosphorylation patterns in relation to drug administration reveals a compound’s molecular mode of action.

Characteristic phosphorylation sites predicting response to treatment, resistance mechanism or synergistic effects can hereby be identified as biomarkers which allow for personalized treatment plans.

Accompanying a clinical trial for the multi-kinase inhibitor Nexavar® in Acute Myeloid Leukemia (AML), KINAXO will apply its phosphoproteomics technology to reveal the drug’s influence on cellular phosphorylation patterns and to search for novel predictive biomarkers.

Nexavar® is already approved for the treatment of hepatocellular (HCC) and renal cell carcinoma (RCC) and shows promising effects in several other indications, amongst them AML, the most common type of leukemia in adults. Despite considerable efforts over the last decades, therapeutic outcome in AML therapy has improved only modestly and remains dismal, with a high number of patients being non-responsive to standard treatment or recurrent.

Application of KINAXO’s phosphoproteomics technology could thus turn out to be a valuable tool to discover predictive biomarkers that foretell therapeutic outcome in patients. Furthermore, quantitative phosphoproteomics will be applied to investigate the molecular efficiency of potential combination therapies in which Nexavar® will be administered together with other targeted drugs to effectively fight cancer. In turn, individualized therapeutic strategies could then improve overall treatment outcome for malignant diseases, such as AML.
Advertisement